Michaela Adamcova

List of Publications by Year
in descending order

70 papers	2,266 citations	201575 27 h-index	223716 46 g-index
71 all docs	71 docs citations	71 times ranked	2810 citing authors

#	Article	IF	Citations
1	Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clinical Science, 2022, 136, 139-161.	1.8	1
2	Characteristics and outcomes of patients admitted for acute heart failure in a singleâ€centre study. ESC Heart Failure, 2022, 9, 2249-2258.	1.4	6
3	Ivabradine improves survival and attenuates cardiac remodeling in isoproterenolâ€induced myocardial injury. Fundamental and Clinical Pharmacology, 2021, 35, 744-748.	1.0	11
4	Reninâ€“Angiotensinâ€“Aldosterone System: Friend or Foeâ€”The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions. International Journal of Molecular Sciences, 2021, 22, 3217.	1.8	18
5	The Impact of microRNAs in Reninâ€“Angiotensin-System-Induced Cardiac Remodelling. International Journal of Molecular Sciences, 2021, 22, 4762.	1.8	19
6	Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model<i>in vivo</i>. Clinical Science, 2021, 135, 1897-1914.	1.8	8
7	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circulation: Heart Failure, 2021, 14, e008209.	1.6	24
8	Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension. Frontiers in Medicine, 2020, 7, 325.	1.2	13
9	Antiarrhythmic Effects of Melatonin and Omega-3 Are Linked with Protection of Myocardial Cx43 Topology and Suppression of Fibrosis in Catecholamine Stressed Normotensive and Hypertensive Rats. Antioxidants, 2020, 9, 546.	2.2	28
10	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II<i>Î²</i>Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 402-415.	1.3	14
11	<i>In vitro</i> and <i>in vivo</i> investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clinical Science, 2019, 133, 1827-1844.	1.8	10
12	Lisinopril reverses behavioural alterations in spontaneously hypertensive rats. General Physiology and Biophysics, 2019, 38, 265-270.	0.4	2
13	Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs. International Journal of Molecular Sciences, 2019, 20, 2638.	1.8	15
14	79â€…Effective cardioprotection against anthracycline cardiotoxicity in isolated cardiomyocytes and rabbits is based on dexrazoxane interaction with topoisomerase II beta instead of iron chelation by its metabolite ADR-925. , 2019, , .		0
15	What prevents cardioprotective drugs from reaching the market?. Expert Review of Clinical Pharmacology, 2018, 11, 463-465.	1.3	4
16	Multiplex biomarker approach to cardiovascular diseases. Acta Pharmacologica Sinica, 2018, 39, 1068-1072.	2.8	29
17	Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. International Journal of Molecular Sciences, 2018, 19, 3017.	1.8	25
18	Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension. Molecules, 2018, 23, 265.	1.7	41

#	Article	IF	Citations
19	Effect of melatonin on the behaviour of rats with continuous light-induced hypertension. General Physiology and Biophysics, 2018, 37, 469-473.	0.4	2
20	Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril. International Journal of Molecular Sciences, 2017, 18, 1612.	1.8	19
21	Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World Journal of Gastroenterology, 2017, 23, 7678-7692.	1.4	13
22	Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. Toxicology, 2016, 372, 52-63.	2.0	1
23	Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Journal of Molecular and Cellular Cardiology, 2016, 91, 92-103.	0.9	20
24	Cardiac troponinsâ€"Translational biomarkers in cardiology: Theory and practice of cardiac troponin highâ€sensitivity assays. BioFactors, 2016, 42, 133-148.	2.6	12
25	Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats. International Journal of Cardiology, 2015, 190, 128-130.	0.8	6
26	Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. International Journal of Cardiology, 2015, 201, 358-367.	0.8	9
27	Hypertension and Cardiovascular Remodelling in Rats Exposed to Continuous Light: Protection by ACE-Inhibition and Melatonin. Mediators of Inflammation, 2014, 2014, 1-10.	1.4	41
28	Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenolâ€induced heart failure. Journal of Pineal Research, 2014, 57, 177-184.	3.4	70
29	Doxorubicin-induced behavioral disturbances in rats: Protective effect of melatonin and captopril. Pharmacology Biochemistry and Behavior, 2014, 124, 284-289.	1.3	31
30	Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up. PLoS ONE, 2014, 9, e96055.	1.1	38
31	Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology, 2013, 311, 191-204.	2.0	28
32	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 468-478.	1.3	48
33	Proteomic insights into chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2011, 50, 849-862.	0.9	57
34	Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment. Journal of Hypertension, 2010, 28, S19-S24.	0.3	15
35	Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. Journal of Hypertension, 2010, 28, S13-S18.	0.3	43
36	Veterinary and toxicological applications for the detection of cardiac injury using cardiac troponin. Veterinary Journal, 2010, 185, 50-57.	0.6	81

#	Article	IF	Citations
37	Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. British Journal of Cancer, 2009, 101, 792-802.	2.9	53
38	Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 2009, 61, 154-171.	1.5	633
39	Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. Journal of Hypertension, 2009, 27, S11-S16.	0.3	35
40	Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. Journal of Hypertension, 2009, 27, S5-S10.	0.3	59
41	Regression of left ventricular hypertrophy and aortic remodelling in NOâ€deficient hypertensive rats: effect of lâ€arginine and spironolactone. Acta Physiologica, 2008, 194, 45-55.	1.8	30
42	Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. British Journal of Pharmacology, 2008, 155, 138-148.	2.7	42
43	Comparison of protection by salicylaldehyde isonicotinoyl hydrazone (SIH) against hydrogen peroxide- and anthracycline-induced toxicity to cardiac cells. Toxicology Letters, 2008, 180, S117.	0.4	0
44	Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity. Hemoglobin, 2008, 32, 207-215.	0.4	8
45	Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 259-269.	1.3	43
46	Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology, 2007, 235, 150-166.	2.0	32
47	In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology, 2007, 237, 218-228.	2.0	55
48	Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1336-1347.	1.3	40
49	Cardiac remodeling and the role of matrix metalloproteinases in chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2006, 40, 1001.	0.9	1
50	Myocardial regulatory proteins and heart failure. European Journal of Heart Failure, 2006, 8, 333-342.	2.9	29
51	Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. BioMetals, 2005, 18, 163-169.	1.8	20
52	Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opinion on Drug Safety, 2005, 4, 457-472.	1.0	64
53	Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Human and Experimental Toxicology, 2005, 24, 581-589.	1.1	12
54	Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacological Research, 2005, 51, 223-231.	3.1	39

#	Article	IF	Citations
55	Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. European Journal of Heart Failure, 2004, 6, 377-387.	2.9	52
56	Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemotherapy and Pharmacology, 2003, 52, 431-434.	1.1	13
57	Troponins in children and neonates. Acta Paediatrica, International Journal of Paediatrics, 2003, 92, 1373-1375.	0.7	10
58	A Study of Potential Toxic Effects After Repeated 10-Week Administration of a New Iron Chelator â€“ Salicylaldehyde Isonicotinoyl Hydrazone (SIH) to Rabbits. Acta Medica (Hradec Kralove), 2003, 46, 163-170.	0.2	17
59	Protein and Phospholipids Composition of Human Myocardium in Children with Congenital Heart Disease. Progress in Experimental Cardiology, 2003, , 37-53.	0.0	1
60	Cardiac troponins following repeated administration of an iron chelator--salicylaldehyde isonicotinoyl hydrazone (SIH)--in rabbits. Acta Medica (Hradec Kralove), 2003, 46, 171-4.	0.2	2
61	Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. Human and Experimental Toxicology, 2002, 21, 649-657.	1.1	36
62	Troponins for predicting cardiotoxic or cardioprotective effects of new drugs. Journal of Molecular and Cellular Cardiology, 2002, 34, A3.	0.9	0
63	Troponins in Experimental Studies. Acta Medica (Hradec Kralove), 2002, 45, 29-32.	0.2	2
64	Troponins in experimental studies. Acta Medica (Hradec Kralove), 2002, 45, 29-32.	0.2	2
65	Regulatory proteins in cardiac muscle of children with congenital heart diseases. Journal of Molecular and Cellular Cardiology, 2001, 33, A1.	0.9	0
66	Protein profile of myocardium in children with congenital heart diseases. Journal of Molecular and Cellular Cardiology, 2001, 33, A92.	0.9	1
67	Cardiac Troponin T in Neonates after Acute and Long-Term Tocolysis. Neonatology, 2000, 78, 288-292.	0.9	16
68	Anthracycline-Induced Cardiotoxicity. Acta Medica (Hradec Kralove), 2000, 43, 75-82.	0.2	57
69	Cardiac troponin T in pregnant women having intravenous tocolytic therapy. Archives of Gynecology and Obstetrics, 1999, 262, 121-126.	0.8	21
70	Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. Journal of Cancer Research and Clinical Oncology, 1999, 125, 268-274.	1.2	39